Fairvalue-Calculator Fairvalue-Calculator
EN DE

Plant Advanced Technologies SA (ALPAT) Fair Value & Analysis

Healthcare · FR · Market cap €7.8M

Price€5.20
Fair Value€8.59
Upside+65.2%
Quality93/100
Evidence: High Range €6.82 – €10.74

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Plant Advanced Technologies SA (ALPAT) currently trades at €5.20, while our model-based Fair Value estimate is €8.59 — implying the stock looks roughly 65.2% undervalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Plant Advanced Technologies SA, a plant biotechnology company, produces and sells actives for cosmetic, pharmaceutical, and agrochemical markets in France. Its technologies include Process PAT Exudactive a sustainable sourcing solution to produce your exclusive, personalized Exudactive; and PAT Target Binding, which finds the ligands that bind to the protein targets of interest, such as enzymes. Plant Advanced Technologies SA was incorporated in 2005 and is headquartered in Vand"uvre-lès-Nancy, France.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Plant Advanced Technologies SA (ALPAT) undervalued?
As of Jun 25, 2026, our model estimates a fair value of €8.59 versus a price of €5.20 — about +65% (undervalued). Model-based estimate, not financial advice.
What is the fair value of ALPAT?
Our 21-model fair value for Plant Advanced Technologies SA is €8.59 (as of Jun 25, 2026), built from audited fundamentals. The current price is €5.20.
What is the quality score of ALPAT?
Plant Advanced Technologies SA has a Quality Score of 93/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.